Paracetamol and ibuprofen for the treatment of fever in children: the PITCH randomised controlled trial
To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home. The trial design was a single-c...
Saved in:
Published in: | Health technology assessment (Winchester, England) Vol. 13; no. 27; pp. iii - iv |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
NIHR Journals Library
01-05-2009
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home.
The trial design was a single-centre (multisite), individually randomised, blinded, three-arm trial comparing paracetamol and ibuprofen together with paracetamol or ibuprofen separately.
There were three recruitment settings, as follows: 'local' where research nurses were recruited from NHS primary care sites; 'remote' where NHS sites notified the study of potentially eligible children; and 'community' where parents contacted the study in response to local media advertisements.
Children aged between 6 months and 6 years with fever > or = 37.8 degrees C and < or = 41 degrees C due to an illness that could be managed at home.
The intervention was the provision of, and advice to give, the medicines for up to 48 hours: paracetamol every 4-6 hours (maximum of four doses in 24 hours) and ibuprofen every 6-8 hours (maximum of three doses in 24 hours). Every parent received two bottles, with at least one containing an active medicine. Parents, research nurses and investigators were blinded to treatment allocation by the use of identically matched placebo medicines. The dose of medicine was determined by the child's weight: paracetamol 15 mg/kg and ibuprofen 10 mg/kg per dose.
For additional time without fever in the first 4 hours, use of both medicines was superior to use of paracetamol alone [adjusted difference 55 minutes, 95% confidence interval (CI) 33 to 77 minutes; p < 0.001] and may have been as good as ibuprofen (adjusted difference 16 minutes, 95% CI -6 to 39 minutes; p = 0.2). Both medicines together cleared the fever 23 minutes (95% CI 2-45 minutes; p = 0.015) faster than paracetamol alone, but no faster than ibuprofen alone (adjusted difference -3 minutes, 95% CI 24-18 minutes; p = 0.8). For additional time without fever in the first 24 hours, both medicines were superior to paracetamol (adjusted difference 4.4 hours, 95% CI 2.4-6.3 hours; p < 0.001) or ibuprofen (adjusted difference 2.5 hours, 95% CI 0.6-4.5 hours; p = 0.008) alone. No reduction in discomfort or other fever-associated symptoms was found, although power was low for these outcomes. An exploratory analysis showed that children with higher discomfort levels had higher mean temperatures. No difference in adverse effects was observed between treatment groups. The recommended maximum number of doses of paracetamol and ibuprofen in 24 hours was exceeded in 8% and 11% of children respectively. Over the 5-day study period, paracetamol and ibuprofen together was the cheapest option for the NHS due to the lower use of health-care services:14 pounds [standard deviation (SD) 23 pounds] versus 20 pounds (SD 38 pounds) for paracetamol and 18 pounds (SD 40 pounds) for ibuprofen. Both medicines were also cheapest for parents because the lower use of health care services resulted in personal saving on travel costs and less time off work: 24 pounds (SD 46 pounds) versus 26 pounds (SD 63 pounds) for paracetamol and 30 pounds (SD 91 pounds) for ibuprofen. This more than compensated for the extra cost of medication. However, statistical evidence for these differences was weak due to lack of power. Overall, a quarter of children were 'back to normal' by 48 hours and one-third by day 5. Five (3%) children were admitted to hospital, two with pneumonia, two with bronchiolitis and one with a severe, but unidentified 'viral illness'.
Young children who are unwell with fever should be treated with ibuprofen first, but the relative risks (inadvertently exceeding the maximum recommended dose) and benefits (extra 2.5 hours without fever) of using paracetamol plus ibuprofen over 24 hours should be considered. However, if two medicines are used, it is recommended that all dose times are carefully recorded to avoid accidentally exceeding the maximum recommended dose. Manufacturers should consider supplying blank charts for this purpose. Use of both medicines should not be discouraged on the basis of cost to either parents or the NHS. Parents and clinicians should be aware that fever is a relatively short-lived symptom, but may have more serious prognostic implications than the other common symptom presentations of childhood. |
---|---|
AbstractList | Objectives: To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home. Design: The trial design was a single-centre (multisite), individually randomised, blinded, three-arm trial comparing paracetamol and ibuprofen together with paracetamol or ibuprofen separately. Setting: There were three recruitment settings, as follows: ‘local’ where research nurses were recruited from NHS primary care sites; ‘remote’ where NHS sites notified the study of potentially eligible children; and ‘community’ where parents contacted the study in response to local media advertisements. Participants: Children aged between 6 months and 6 years with fever ≥ 37.8°C and ≤ 41°C due to an illness that could be managed at home. Interventions: The intervention was the provision of, and advice to give, the medicines for up to 48 hours: paracetamol every 4–6 hours (maximum of four doses in 24 hours) and ibuprofen every 6–8 hours (maximum of three doses in 24 hours). Every parent received two bottles, with at least one containing an active medicine. Parents, research nurses and investigators were blinded to treatment allocation by the use of identically matched placebo medicines. The dose of medicine was determined by the child’s weight: paracetamol 15 mg/kg and ibuprofen 10 mg/kg per dose. Results: For additional time without fever in the first 4 hours, use of both medicines was superior to use of paracetamol alone [adjusted difference 55 minutes, 95% confidence interval (CI) 33 to 77 minutes; p < 0.001] and may have been as good as ibuprofen (adjusted difference 16 minutes, 95% CI –6 to 39 minutes; p = 0.2). Both medicines together cleared the fever 23 minutes (95% CI 2–45 minutes; p = 0.015) faster than paracetamol alone, but no faster than ibuprofen alone (adjusted difference –3 minutes, 95% CI 24–18 minutes; p = 0.8). For additional time without fever in the first 24 hours, both medicines were superior to paracetamol (adjusted difference 4.4 hours, 95% CI 2.4–6.3 hours; p < 0.001) or ibuprofen (adjusted difference 2.5 hours, 95% CI 0.6–4.5 hours; p = 0.008) alone. No reduction in discomfort or other fever-associated symptoms was found, although power was low for these outcomes. An exploratory analysis showed that children with higher discomfort levels had higher mean temperatures. No difference in adverse effects was observed between treatment groups. The recommended maximum number of doses of paracetamol and ibuprofen in 24 hours was exceeded in 8% and 11% of children respectively. Over the 5-day study period, paracetamol and ibuprofen together was the cheapest option for the NHS due to the lower use of health-care services: £14 [standard deviation (SD) £23] versus £20 (SD £38) for paracetamol and £18 (SD £40) for ibuprofen. Both medicines were also cheapest for parents because the lower use of health care services resulted in personal saving on travel costs and less time off work: £24 (SD £46) versus £26 (SD £63) for paracetamol and £30 (SD £91) for ibuprofen. This more than compensated for the extra cost of medication. However, statistical evidence for these differences was weak due to lack of power. Overall, a quarter of children were ‘back to normal’ by 48 hours and one-third by day 5. Five (3%) children were admitted to hospital, two with pneumonia, two with bronchiolitis and one with a severe, but unidentified ‘viral illness’. Conclusions: Young children who are unwell with fever should be treated with ibuprofen first, but the relative risks (inadvertently exceeding the maximum recommended dose) and benefits (extra 2.5 hours without fever) of using paracetamol plus ibuprofen over 24 hours should be considered. However, if two medicines are used, it is recommended that all dose times are carefully recorded to avoid accidentally exceeding the maximum recommended dose. Manufacturers should consider supplying blank charts for this purpose. Use of both medicines should not be discouraged on the basis of cost to either parents or the NHS. Parents and clinicians should be aware that fever is a relatively short-lived symptom, but may have more serious prognostic implications than the other common symptom presentations of childhood. Trial registration: Current Controlled Trials ISRCTN 26362730. OBJECTIVESTo establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home. DESIGNThe trial design was a single-centre (multisite), individually randomised, blinded, three-arm trial comparing paracetamol and ibuprofen together with paracetamol or ibuprofen separately. SETTINGThere were three recruitment settings, as follows: 'local' where research nurses were recruited from NHS primary care sites; 'remote' where NHS sites notified the study of potentially eligible children; and 'community' where parents contacted the study in response to local media advertisements. PARTICIPANTSChildren aged between 6 months and 6 years with fever > or = 37.8 degrees C and < or = 41 degrees C due to an illness that could be managed at home. INTERVENTIONSThe intervention was the provision of, and advice to give, the medicines for up to 48 hours: paracetamol every 4-6 hours (maximum of four doses in 24 hours) and ibuprofen every 6-8 hours (maximum of three doses in 24 hours). Every parent received two bottles, with at least one containing an active medicine. Parents, research nurses and investigators were blinded to treatment allocation by the use of identically matched placebo medicines. The dose of medicine was determined by the child's weight: paracetamol 15 mg/kg and ibuprofen 10 mg/kg per dose. RESULTSFor additional time without fever in the first 4 hours, use of both medicines was superior to use of paracetamol alone [adjusted difference 55 minutes, 95% confidence interval (CI) 33 to 77 minutes; p < 0.001] and may have been as good as ibuprofen (adjusted difference 16 minutes, 95% CI -6 to 39 minutes; p = 0.2). Both medicines together cleared the fever 23 minutes (95% CI 2-45 minutes; p = 0.015) faster than paracetamol alone, but no faster than ibuprofen alone (adjusted difference -3 minutes, 95% CI 24-18 minutes; p = 0.8). For additional time without fever in the first 24 hours, both medicines were superior to paracetamol (adjusted difference 4.4 hours, 95% CI 2.4-6.3 hours; p < 0.001) or ibuprofen (adjusted difference 2.5 hours, 95% CI 0.6-4.5 hours; p = 0.008) alone. No reduction in discomfort or other fever-associated symptoms was found, although power was low for these outcomes. An exploratory analysis showed that children with higher discomfort levels had higher mean temperatures. No difference in adverse effects was observed between treatment groups. The recommended maximum number of doses of paracetamol and ibuprofen in 24 hours was exceeded in 8% and 11% of children respectively. Over the 5-day study period, paracetamol and ibuprofen together was the cheapest option for the NHS due to the lower use of health-care services:14 pounds [standard deviation (SD) 23 pounds] versus 20 pounds (SD 38 pounds) for paracetamol and 18 pounds (SD 40 pounds) for ibuprofen. Both medicines were also cheapest for parents because the lower use of health care services resulted in personal saving on travel costs and less time off work: 24 pounds (SD 46 pounds) versus 26 pounds (SD 63 pounds) for paracetamol and 30 pounds (SD 91 pounds) for ibuprofen. This more than compensated for the extra cost of medication. However, statistical evidence for these differences was weak due to lack of power. Overall, a quarter of children were 'back to normal' by 48 hours and one-third by day 5. Five (3%) children were admitted to hospital, two with pneumonia, two with bronchiolitis and one with a severe, but unidentified 'viral illness'. CONCLUSIONSYoung children who are unwell with fever should be treated with ibuprofen first, but the relative risks (inadvertently exceeding the maximum recommended dose) and benefits (extra 2.5 hours without fever) of using paracetamol plus ibuprofen over 24 hours should be considered. However, if two medicines are used, it is recommended that all dose times are carefully recorded to avoid accidentally exceeding the maximum recommended dose. Manufacturers should consider supplying blank charts for this purpose. Use of both medicines should not be discouraged on the basis of cost to either parents or the NHS. Parents and clinicians should be aware that fever is a relatively short-lived symptom, but may have more serious prognostic implications than the other common symptom presentations of childhood. To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home. The trial design was a single-centre (multisite), individually randomised, blinded, three-arm trial comparing paracetamol and ibuprofen together with paracetamol or ibuprofen separately. There were three recruitment settings, as follows: 'local' where research nurses were recruited from NHS primary care sites; 'remote' where NHS sites notified the study of potentially eligible children; and 'community' where parents contacted the study in response to local media advertisements. Children aged between 6 months and 6 years with fever > or = 37.8 degrees C and < or = 41 degrees C due to an illness that could be managed at home. The intervention was the provision of, and advice to give, the medicines for up to 48 hours: paracetamol every 4-6 hours (maximum of four doses in 24 hours) and ibuprofen every 6-8 hours (maximum of three doses in 24 hours). Every parent received two bottles, with at least one containing an active medicine. Parents, research nurses and investigators were blinded to treatment allocation by the use of identically matched placebo medicines. The dose of medicine was determined by the child's weight: paracetamol 15 mg/kg and ibuprofen 10 mg/kg per dose. For additional time without fever in the first 4 hours, use of both medicines was superior to use of paracetamol alone [adjusted difference 55 minutes, 95% confidence interval (CI) 33 to 77 minutes; p < 0.001] and may have been as good as ibuprofen (adjusted difference 16 minutes, 95% CI -6 to 39 minutes; p = 0.2). Both medicines together cleared the fever 23 minutes (95% CI 2-45 minutes; p = 0.015) faster than paracetamol alone, but no faster than ibuprofen alone (adjusted difference -3 minutes, 95% CI 24-18 minutes; p = 0.8). For additional time without fever in the first 24 hours, both medicines were superior to paracetamol (adjusted difference 4.4 hours, 95% CI 2.4-6.3 hours; p < 0.001) or ibuprofen (adjusted difference 2.5 hours, 95% CI 0.6-4.5 hours; p = 0.008) alone. No reduction in discomfort or other fever-associated symptoms was found, although power was low for these outcomes. An exploratory analysis showed that children with higher discomfort levels had higher mean temperatures. No difference in adverse effects was observed between treatment groups. The recommended maximum number of doses of paracetamol and ibuprofen in 24 hours was exceeded in 8% and 11% of children respectively. Over the 5-day study period, paracetamol and ibuprofen together was the cheapest option for the NHS due to the lower use of health-care services:14 pounds [standard deviation (SD) 23 pounds] versus 20 pounds (SD 38 pounds) for paracetamol and 18 pounds (SD 40 pounds) for ibuprofen. Both medicines were also cheapest for parents because the lower use of health care services resulted in personal saving on travel costs and less time off work: 24 pounds (SD 46 pounds) versus 26 pounds (SD 63 pounds) for paracetamol and 30 pounds (SD 91 pounds) for ibuprofen. This more than compensated for the extra cost of medication. However, statistical evidence for these differences was weak due to lack of power. Overall, a quarter of children were 'back to normal' by 48 hours and one-third by day 5. Five (3%) children were admitted to hospital, two with pneumonia, two with bronchiolitis and one with a severe, but unidentified 'viral illness'. Young children who are unwell with fever should be treated with ibuprofen first, but the relative risks (inadvertently exceeding the maximum recommended dose) and benefits (extra 2.5 hours without fever) of using paracetamol plus ibuprofen over 24 hours should be considered. However, if two medicines are used, it is recommended that all dose times are carefully recorded to avoid accidentally exceeding the maximum recommended dose. Manufacturers should consider supplying blank charts for this purpose. Use of both medicines should not be discouraged on the basis of cost to either parents or the NHS. Parents and clinicians should be aware that fever is a relatively short-lived symptom, but may have more serious prognostic implications than the other common symptom presentations of childhood. |
Author | Fletcher, M Costelloe, C Hay, A D Hollinghurst, S Montgomery, A A Peters, T J Redmond, N M |
Author_xml | – sequence: 1 givenname: A D surname: Hay fullname: Hay, A D organization: Academic Unit of Primary Health Care, NIHR National School for Primary Care Research, Department of Community Based Medicine, University of Bristol, Bristol, UK – sequence: 2 givenname: N M surname: Redmond fullname: Redmond, N M – sequence: 3 givenname: C surname: Costelloe fullname: Costelloe, C – sequence: 4 givenname: A A surname: Montgomery fullname: Montgomery, A A – sequence: 5 givenname: M surname: Fletcher fullname: Fletcher, M – sequence: 6 givenname: S surname: Hollinghurst fullname: Hollinghurst, S – sequence: 7 givenname: T J surname: Peters fullname: Peters, T J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19454182$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkV1LHTEQhkOx1KMt-AskV8WbtflO1rsiVQ8IetFeh2wy8axkE5vNEfrvXT2nepUhPPMMM-8ROsglA0InlJxzTsmPTXOUM00-oRUjQnWiZ-IArShXqpNMm0N0NM-PhAiqJP2CDmkvpKCGrdDDvavOQ3NTSdjlgMdh-1RLhIxjqbhtALcKrk2QGy4RR3iGiseM_WZMoUK-eGPu178vb3BdBGUaZwjYl9xqSWkpWx1d-oo-R5dm-LZ_j9Gfq19LT3d7d72-_HnbeW5o68wgtddEkegphJ6IwQhJPfSghJFESso4eNA0BjkI1UdOgVHdQ9DS-AH4MVrvvKG4R_tUx8nVf7a40b59lPpgXW2jT2Cd19pLogQnUhgt3aCdcERyE3g_SL-4vu9cy0H-bmFudtnNQ0ouQ9nOVmmmCDN6Ac92oK9lnivE98GU2NeA7P-AFvR079wOE4QPcJ8IfwH5G4yC |
CitedBy_id | crossref_primary_10_1097_INF_0000000000002452 crossref_primary_10_1111_bcp_13173 crossref_primary_10_4094_jkachn_2010_16_1_30 crossref_primary_10_1002_prp2_925 crossref_primary_10_1002_14651858_CD011534_pub2 crossref_primary_10_1002_14651858_CD011534_pub3 crossref_primary_10_1177_1367493513496663 crossref_primary_10_1542_peds_2009_3352 crossref_primary_10_17795_zjrms_7952 crossref_primary_10_1016_S0031_3939_10_70072_X crossref_primary_10_1007_s12663_013_0611_7 crossref_primary_10_1111_j_1365_2702_2010_03258_x crossref_primary_10_1016_j_clinthera_2012_06_011 crossref_primary_10_21518_2079_701X_2018_11_158_161 crossref_primary_10_1111_j_1524_4733_2010_00788_x crossref_primary_10_21518_2079_701X_2019_2_106_112 crossref_primary_10_4094_jkachn_2010_16_4_324 crossref_primary_10_1007_s10787_009_0016_x crossref_primary_10_1007_s40258_022_00780_7 crossref_primary_10_1177_0009922816678818 crossref_primary_10_1007_s00431_013_2239_5 crossref_primary_10_21508_1027_4065_2020_65_3_153_159 crossref_primary_10_3109_03639045_2011_605141 crossref_primary_10_3389_fped_2019_00217 crossref_primary_10_1186_s13063_022_06187_y crossref_primary_10_3310_hta24370 crossref_primary_10_1016_j_therap_2020_04_005 crossref_primary_10_1016_j_amjoto_2018_10_012 crossref_primary_10_1007_s40268_014_0052_x crossref_primary_10_1111_apa_13566 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 DOA |
DOI | 10.3310/hta13270 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2046-4924 |
EndPage | iv |
ExternalDocumentID | oai_doaj_org_article_ac77c50643054875ab7a4a0538d39b5c 10_3310_hta13270 19454182 |
Genre | Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Department of Health – fundername: Department of Health grantid: 03/09/01 |
GroupedDBID | --- 53G 5GY ADBBV ADDVE AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL BCNDV CGR CUY CVF CZQ DIK EBS ECM EIF EJD F5P GROUPED_DOAJ NPM OK1 P2P P6G TR2 W2D AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c381t-8b57c7060fc1ed904b8451ce9e6485055123ece71fd5b469f31e2179ed758cbe3 |
IEDL.DBID | DOA |
ISSN | 1366-5278 |
IngestDate | Tue Oct 22 14:50:37 EDT 2024 Sat Jun 22 21:01:20 EDT 2024 Fri Aug 23 02:06:05 EDT 2024 Sun Jun 23 00:28:06 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 27 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c381t-8b57c7060fc1ed904b8451ce9e6485055123ece71fd5b469f31e2179ed758cbe3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 |
OpenAccessLink | https://doaj.org/article/ac77c50643054875ab7a4a0538d39b5c |
PMID | 19454182 |
PQID | 67260287 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_ac77c50643054875ab7a4a0538d39b5c proquest_miscellaneous_67260287 crossref_primary_10_3310_hta13270 pubmed_primary_19454182 |
PublicationCentury | 2000 |
PublicationDate | 2009-May 2009-05-00 20090501 2009-05-01 |
PublicationDateYYYYMMDD | 2009-05-01 |
PublicationDate_xml | – month: 05 year: 2009 text: 2009-May |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Health technology assessment (Winchester, England) |
PublicationTitleAlternate | Health Technol Assess |
PublicationYear | 2009 |
Publisher | NIHR Journals Library |
Publisher_xml | – name: NIHR Journals Library |
References | 19949176 - Evid Based Med. 2009 Dec;14(6):174 |
References_xml | |
SSID | ssj0041651 |
Score | 2.1845562 |
Snippet | To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for... OBJECTIVESTo establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen... Objectives: To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen... |
SourceID | doaj proquest crossref pubmed |
SourceType | Open Website Aggregation Database Index Database |
StartPage | iii |
SubjectTerms | Acetaminophen - administration & dosage Acetaminophen - economics Acetaminophen - therapeutic use Analgesics, Non-Narcotic - administration & dosage Analgesics, Non-Narcotic - economics Analgesics, Non-Narcotic - therapeutic use Child Child, Preschool Cost-Benefit Analysis Double-Blind Method Drug Therapy, Combination Female fever Fever - drug therapy fever-associated discomfort Humans ibuprofen Ibuprofen - administration & dosage Ibuprofen - economics Ibuprofen - therapeutic use Infant Male paracetamol |
Title | Paracetamol and ibuprofen for the treatment of fever in children: the PITCH randomised controlled trial |
URI | https://www.ncbi.nlm.nih.gov/pubmed/19454182 https://search.proquest.com/docview/67260287 https://doaj.org/article/ac77c50643054875ab7a4a0538d39b5c |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3JTsMwELWgB8QFsRNWI3GN2jRObHNjaVUOoEqAxC3yMoZKJUE0-X_GWQoXxIVblORgzYz83pPHbwi5UH7uowYWItV2IUMIC7U0LjQSwcEDUKT95eTJI394Ebcjb5OzHPXle8Iae-AmcH1lODfeVQ0L05NrpbliCktH2FjqxNS77yDtxFSzByPLSNobVylKLS4a29kYuUz_rVSowPxw4h9AVPv1_04ya7AZb5KNliXSq2Z1W2QF8m2ydt-eg--Q16m3WYZSvRdzqnJLZ7ry07chp0hCKZI6uuwgp4WjDrBi6Syn3d3ty_qf6d3TzYQiWtkC0w2Wto3rc3ysx3nskufxCP8J25EJoUHoLUOhE268IY4zEVg5YFqwJDIgIWUCyQ7CewwGeORsolEZuzgCFCUSLOoGoyHeI728yOGA0KEdCiH5YOiUQQSTmjuDElYkkMRKWBaQ8y5-2UfjjJGhovAxzroYB-TaB3b53XtZ1y8ww1mb4eyvDAfkrEtLhsHwBxoqh6JaZClHNYaSLyD7Tba-FyJZwlA6Hf7HAo7IenOG5Nscj0mv_KzghKwubHVaV90XjePY3Q |
link.rule.ids | 315,782,786,866,2106,27933,27934 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Paracetamol+and+ibuprofen+for+the+treatment+of+fever+in+children%3A+the+PITCH+randomised+controlled+trial&rft.jtitle=Health+technology+assessment+%28Winchester%2C+England%29&rft.au=Hay%2C+A+D&rft.au=Redmond%2C+N+M&rft.au=Costelloe%2C+C&rft.au=Montgomery%2C+A+A&rft.date=2009-05-01&rft.eissn=2046-4924&rft.volume=13&rft.issue=27&rft.spage=iii&rft.epage=iv&rft_id=info:doi/10.3310%2Fhta13270&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1366-5278&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1366-5278&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1366-5278&client=summon |